Real-world use of the updated refractory epilepsy screening tool for Lennox-Gastaut syndrome.

Lennox–Gastaut syndrome diagnosis screening tool treatment‐resistant epilepsy

Journal

Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036

Informations de publication

Date de publication:
10 May 2024
Historique:
revised: 14 03 2024
received: 19 10 2023
accepted: 10 04 2024
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 10 5 2024
Statut: aheadofprint

Résumé

To evaluate the Refractory Epilepsy Screening Tool for Lennox-Gastaut Syndrome (REST-LGS) for real-world identification of LGS in adults and to develop a scoring system for the tool. A retrospective chart review of adults with drug resistant epilepsy (DRE) and intellectual development disorder (IDD) was conducted by 2 primary care providers blinded to diagnosis. The REST-LGS was designed via the Modified Delphi Consensus and was previously validated. This tool consists of 8 criteria (4 major, 4 minor) considered indicative of LGS. To account for missing data in the earlier validation study and to evaluate applicability in a real-world setting, the REST-LGS was refined to include a scoring system in which major criteria were more heavily weighted than minor criteria, producing categories of "likely" (>11 points), "possible" (8-11 points), and "unlikely" (<8 points) LGS. Statistical analyses were descriptive. Of the 100 patients included in the analysis, data for slow spike-waves in electroencephalography and seizure onset age - both major REST-LGS criteria - were missing for 46% and 42% of patients, respectively. The majority of patients met 4 of the 8 REST-LGS criteria (cognitive impairment since childhood, 71%; persistent seizures despite a trial of ≥2 antiseizure medications, 65%; seizure onset before the age of 12 years, 57%; ≥2 seizure types, 56%). All 4 major criteria were met in 22 patients (22%). The percentages of patients considered "likely," "possible," or "unlikely" to have LGS were 26%, 30%, and 44%, respectively. Of the 74 patients without a previous LGS diagnosis, 42 (57%) were identified as "possible" or "likely" to have LGS using REST-LGS. In this analysis, the validated REST-LGS was evaluated in a real-world setting. The majority of previously undiagnosed patients were identified via REST-LGS as "possible" or "likely" to have LGS. Extensive missing data highlights challenges of LGS diagnosis in adults. There is a need to identify adult patients with Lennox-Gastaut syndrome (LGS) so they can receive appropriate treatment. The Refractory Epilepsy Screening Tool for LGS (REST-LGS) questionnaire was designed by experts to identify whether patients with seizures that are not controlled by medications may have LGS. In this study, 2 physicians completed the REST-LGS using charts for 100 patients who experience seizures not controlled by medications. Of the patients who were previously diagnosed as not having LGS, the majority were "likely" or "possible" to have LGS based on the REST-LGS; therefore, the REST-LGS can identify patients for further evaluation.

Identifiants

pubmed: 38726917
doi: 10.1002/epi4.12952
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Jazz Pharmaceuticals, Inc.

Informations de copyright

© 2024 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Références

Arzimanoglou A, Resnick T. All children who experience epileptic falls do not necessarily have Lennox‐Gastaut syndrome… but many do. Epileptic Disord. 2011;13(Suppl 1):S3–S13.
Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1398–1442.
Bourgeois BF, Douglass LM, Sankar R. Lennox‐Gastaut syndrome: a consensus approach to differential diagnosis. Epilepsia. 2014;55(Suppl 4):4–9.
Oguni H, Hayashi K, Osawa M. Long‐term prognosis of Lennox‐Gastaut syndrome. Epilepsia. 1996;37(Suppl 3):44–47.
Camfield PR. Definition and natural history of Lennox‐Gastaut syndrome. Epilepsia. 2011;52(Suppl 5):3–9.
Ferlazzo E, Nikanorova M, Italiano D, Bureau M, Dravet C, Calarese T, et al. Lennox‐Gastaut syndrome in adulthood: clinical and EEG features. Epilepsy Res. 2010;89(2–3):271–277.
Piña‐Garza JE, Chung S, Montouris GD, Radtke RA, Resnick T, Wechsler RT. Challenges in identifying Lennox‐Gastaut syndrome in adults: a case series illustrating its changing nature. Epilepsy Behav Case Rep. 2016;5:38–43.
Yagi K. Evolution of Lennox‐Gastaut syndrome: a long‐term longitudinal study. Epilepsia. 1996;37(Suppl 3):48–51.
Al‐Banji MH, Zahr DK, Jan MM. Lennox‐Gastaut syndrome. Management update. Neurosciences (Riyadh, Saudi Arabia). 2015;20(3):207–212.
Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert opinion on the management of Lennox‐Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol. 2017;8:505.
Kerr M, Kluger G, Philip S. Evolution and management of Lennox‐Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue? Epileptic Disord. 2011;13(Suppl 1):S15–S26.
Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M, et al. Lennox‐Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93.
Piña‐Garza JE, Boyce D, Tworek DM, Davis KA, Gatens H, Lai G, et al. The refractory epilepsy screening tool for Lennox‐Gastaut syndrome (REST‐LGS). Epilepsy Behav. 2019;90:148–153.
Marchese F, Cappelletti S, Filippini M, Guido CA, Passamonti C, Pucci B, et al. Comorbidities in Dravet syndrome and Lennox–Gastaut syndrome. SN Comprehen Clin Med. 2021;3(10):2167–2179.
Montouris G, Aboumatar S, Burdette D, Kothare S, Kuzniecky R, Rosenfeld W, et al. Expert opinion: proposed diagnostic and treatment algorithms for Lennox‐Gastaut syndrome in adult patients. Epilepsy Behav. 2020;110:107146.
Resnick T, Sheth RD. Early diagnosis and treatment of Lennox‐Gastaut syndrome. J Child Neurol. 2017;32(11):947–955.
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–1077.
Hasan TF, Tatum WO. When should we obtain a routine EEG while managing people with epilepsy? Epilepsy & Behavior Reports. 2021;16:100454.
Slifer KJ, Avis KT, Frutchey RA. Behavioral intervention to increase compliance with electroencephalographic procedures in children with developmental disabilities. Epilepsy Behav. 2008;13(1):189–195.
van Rijckevorsel K. Treatment of Lennox‐Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat. 2008;4(6):1001–1019.
Tomson T, Surges R, Delamont R, Haywood S, Hesdorffer DC. Who to target in sudden unexpected death in epilepsy prevention and how? Risk factors, biomarkers, and intervention study designs. Epilepsia. 2016;57(Suppl 1):4–16.
Reisman M. EHRs: the challenge of making electronic data usable and interoperable. P T. 2017;42(9):572–575.
United States Food and Drug Administration. 21st Century Cures Act. 2020 https://www.fda.gov/regulatory‐information/selected‐amendments‐fdc‐act/21st‐century‐cures‐act. [Accessed June 7, 2023].
Strzelczyk A, Schubert‐Bast S. Expanding the treatment landscape for Lennox‐Gastaut syndrome: current and future strategies. CNS Drugs. 2021;35(1):61–83.

Auteurs

Steven M Wolf (SM)

Boston Children's Hospital Physicians, Hawthorne, New York, USA.
New York Medical College, Valhalla, New York, USA.

Danielle Boyce (D)

Tufts University School of Medicine, Boston, Massachusetts, USA.
Johns Hopkins School of Medicine, Biomedical Informatics and Data Science, Baltimore, Maryland, USA.

Patricia Peña (P)

New York Medical College, Valhalla, New York, USA.

Jesus Eric Piña-Garza (JE)

The Children's Hospital at TriStar Centennial, Nashville, Tennessee, USA.

Jessica J Roland (JJ)

Jazz Pharmaceuticals, Inc., Carlsbad, California, USA.

Bethany Thomas (B)

Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Donika Zogejani (D)

New York Medical College, Valhalla, New York, USA.

Patricia E McGoldrick (PE)

Boston Children's Hospital Physicians, Hawthorne, New York, USA.
New York Medical College, Valhalla, New York, USA.

Classifications MeSH